CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study

计划入组 3 人 · 首次发布于 2020 年 9 月 17 日

HER2 Expression Detection and Radionuclide Therapy in Breast Cancer Using 99mTc/188Re Labeled Single Domain Antibody

计划入组 43 人 · 首次发布于 2020 年 12 月 19 日

Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer

计划入组 330 人 · 首次发布于 2013 年 4 月 25 日

Marine collagen, soluble

Recombinant anti-HER2 domain II and domain IV bispecific antibody-MMAE conjugate (Xuanzhu)

small soluble presenilin

Domain Therapeutics SA

France

Zymeworks

Canada

Lifecore Biomedical

United States

Soluble HER2 Drives CD8⁺ T-Cell Exhaustion and Limits Immunotherapy Response in HER2-Low Triple-Negative Breast Cancer

Distinct Mechanisms of HER2-Targeting Agents in NSCLC: Understanding TKIs vs ADCs

HER2-Positive Gastric Cancer Pipeline Shows Robust Activity with 20+ Companies Developing Novel Therapies